AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc.

AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, announced today that the Company has signed a binding term sheet to acquire leading oncology research and development company Sapphire Biotech, Inc. (“Sapphire”) as a wholly-owned subsidiary. AXIM and Sapphire intend to enter into Definitive Documents for the transaction no later than February 28, 2020. However, the binding Term Sheet will remain in full force and effect until such time as the Definitive Documents are executed by the parties or until the Term Sheet is terminated by mutual consent of the parties. Sapphire is a research and development company that aims to improve global cancer care through the development of proprietary therapeutics for inhibiting cancer growth and metastasis.

Read the full article: AXIM® Biotechnologies to Acquire Leading Oncology Research and Development Company Sapphire Biotech, Inc. //

Source: https://www.globenewswire.com/news-release/2020/01/08/1967886/0/en/AXIM-Biotechnologies-to-Acquire-Leading-Oncology-Research-and-Development-Company-Sapphire-Biotech-Inc.html

Scroll to Top